Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome

Deferasirox-induced urticarial vasculitis in a patient with myelodysplastic syndrome*

Deferasirox is an iron chelator agent used in the treatment of diseases with iron overload, such as thalassemia and myelodysplastic syndrome. Although the majority of adverse reactions of deferasirox involve gastrointestinal symptoms and increase in serum creatinine and transaminases, skin rashes, such as maculopapular and urticarial eruptions, have also been reported. This study reports a case...

central nervous system vasculitis in a patient with myelodysplastic syndrome

myelodysplastic syndromes (mds) are a group of hematological disorders ranging from chronic refractory anemia to leukemia. there are some reports about association of mds with autoimmune disorders and vasculitis. in this study we describe a patient with mds and vasculitis presenting with central nervous system (cns) involvement. a clinical response to immunosuppressive therapy was also observed...

Urticarial vasculitis and Schnitzler syndrome.

Both urticarial vasculitis and Schnitzler syndrome are serious diseases but a recently gained better understanding of their underlying pathomechanism allows better treatment options than only a decade ago.

Plasmapheresis in a Patient With "Refractory" Urticarial Vasculitis

Immune complexes are found in the circulation of 30%-75% of patients with urticarial vasculitis and much evidence supports the role of these immune complexes in the pathogenesis of urticarial vasculitis. Plasmapheresis is effective for removing these immune complexes; however, there are few reports on the use of plasmapheresis in the treatment of urticarial vasculitis. We describe a case of "re...

Urticarial vasculitis induced by fluoxetine.